INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 436m ago
House PTR36m ago
SEC 13F35m ago
Robinhood Chain35m ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,525 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
23
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$1.12M
16.2K sh
Jan 9, 2026Jan 13, 2026
Page 1490 of 1814
← PrevNext →
traded Jan 9, 2026
+4d
SEC Form 4

Evidence

23
LJ
Labe JamesDirector, Chief Executive Officer
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$159K
23.8K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

23
SS
Srivastava SajalDirector, President and CIO
TPVGTriplePoint Venture Growth BDC Corp.
Open-market purchase · 10b5-1 plan
BUY$159K
23.8K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

22
PS
Peters John SheldonChief Insurance Officer
LMNDLemonade, Inc.
Option exercise
M$97K
18.5K sh
Jan 8, 2026Jan 13, 2026
traded Jan 8, 2026
+5dSEC Form 4

Evidence

22
MR
McHugh RyanVP, CAO & Assistant Treasurer
MAINMain Street Capital CORP
Other acquisition or disposition
J$1,629
27 sh
Dec 29, 2025Jan 13, 2026
traded Dec 29, 2025
+15dSEC Form 4

Evidence

22
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$426K
1,636 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

22
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$314K
1,200 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

22
KB
Kalra BalkrishanDirector, President and CEO
GGenpact LTD
Tax withholding
F$1.43M
29.7K sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

22
MR
McHugh RyanVP, CAO & Assistant Treasurer
MAINMain Street Capital CORP
Other acquisition or disposition
J$2,006
33 sh
Dec 29, 2025Jan 13, 2026
traded Dec 29, 2025
+15dSEC Form 4

Evidence

22
MR
McHugh RyanVP, CAO & Assistant Treasurer
MAINMain Street Capital CORP
Other acquisition or disposition
J$1,717
28 sh
Dec 15, 2025Jan 13, 2026
traded Dec 15, 2025
+29dSEC Form 4

Evidence

22
MR
McHugh RyanVP, CAO & Assistant Treasurer
MAINMain Street Capital CORP
Other acquisition or disposition
J$1,379
22 sh
Dec 15, 2025Jan 13, 2026
traded Dec 15, 2025
+29dSEC Form 4

Evidence

21
TF
Tematio Jean FelixVP, CAO & Corporate Controller
UGIUGI CORP /PA/
Option exercise
M—
2,930 sh
Jan 11, 2026Jan 13, 2026
traded Jan 11, 2026
+2dSEC Form 4

Evidence

21
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
93.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

21
CV
Caldwell Nick V.Chief Product Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$530K
75.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

21
CE
Claypoole Robert EDirector, President and CEO
BVSBioventus Inc.
Option exercise
M—
93.8K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

21
SA
Schwaneke Jeffrey A.Chief Financial Officer
AGLagilon health, inc.
Grant or award
A—
600.0K sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

21
NJ
Nisco JamesSVP, Fin/Treas, Chief Actg Off
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
15.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

21
IT
Imam TariqSVP, Bus Dev, General Counsel
LSTALISATA THERAPEUTICS, INC.
Grant or award
A—
15.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
DS
Dewan SameerSenior Vice President
GGenpact LTD
Open-market sale · 10b5-1 plan
SELL$704K
15.1K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

20
VR
Vashisht RijuSenior Vice President
GGenpact LTD
Open-market sale · 10b5-1 plan
SELL$747K
16.0K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

20
NK
Nakamura KatsufumiSVP, Chief Customer Officer
ADIANALOG DEVICES INC
Open-market sale
SELL$151K
500 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
TC
Thygesen Allan C.Director, President and CEO
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$686K
9,799 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
HB
Horowitz BradleyDirector
CRCLCircle Internet Group, Inc.
Other acquisition or disposition
J—
117 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
GJ
Grayson Blake JeffreyChief Financial Officer
DOCUDOCUSIGN, INC.
Open-market sale · 10b5-1 plan
SELL$455K
6,500 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
UM
Urist MarshallEVP, Research & Investments
RPRXRoyalty Pharma plc
Open-market sale · 10b5-1 plan
SELL$816K
20.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

20
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
100 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.03M
1,996 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$194K
738 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.27M
2,450 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
WH
Weiner Michael HalChief Financial Officer
GGenpact LTD
Tax withholding
F$580K
12.0K sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

19
NA
Nanduru AnilSenior Vice President
GGenpact LTD
Tax withholding
F$573K
11.9K sh
Jan 10, 2026Jan 13, 2026
traded Jan 10, 2026
+3dSEC Form 4

Evidence

19
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.28M
2,432 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
PA
Patel AnishCHIEF OPERATING OFFICER
ELVNEnliven Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.34M
48.1K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
HR
Howard Justyn RussellDirector, Executive Chair, 10% Owner
SPTSprout Social, Inc.
Open-market sale · 10b5-1 plan
SELL$428K
40.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

19
AK
Ahn KennethPresident, Hagerty Marketplace
HGTYHagerty, Inc.
Open-market sale · 10b5-1 plan
SELL$643K
50.0K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

19
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$1.06M
2,044 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

18
GK
Gant Kelli K.See remarks
HCCWARRIOR MET COAL, INC.
Open-market sale · 10b5-1 plan
SELL$1.00M
10.0K sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$205K
6,348 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

18
BS
Baig SaqibChief Accounting Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$69K
10.0K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

18
RM
Rodman David MalcomChief Medical Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$72K
2,170 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence